Cases & Deals

Actimis develops patent portfolio for CRTH2 and CCR3 modulators

Clients Actimis Pharmaceuticals, Inc.

Representing Actimis Pharmaceuticals, Inc., Jones Day assisted with the development of patent portfolios for small molecule drugs relating to CRTH2 and CCR3 modulators.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.